Impact of variation in CYP3A and CYP2C8 on tucatinib metabolic clearance in human liver microsomes
{{output}}
Tucatinib is a small molecule tyrosine kinase inhibitor indicated for HER2-positive breast cancer. This recently approved drug is primarily metabolized by cytochrome P450 (P450) 2C8 and CYP3A. Given the interindividual variability in the pharmacokinetics of so... ...
